Crescent Biopharma (CBIO) Operating Expenses (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Operating Expenses data on file, last reported at $25.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $25.8 million, up 81.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $175.0 million (up 294.15% YoY), and the FY2025 annual result was $163.5 million, up 308.29% from the prior year.
• Operating Expenses slipped to $25.8 million in Q1 2026 per CBIO's latest filing, from $102.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $102.3 million in Q4 2025 and troughed at $2.6 million in Q3 2024.
• A 5-year average of $18.7 million and a median of $11.1 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses plunged 73.19% in 2024, then soared 883.85% in 2025.
• A 5-year view of Operating Expenses shows it stood at $10.6 million in 2022, then dropped by 9.62% to $9.6 million in 2023, then jumped by 79.06% to $17.2 million in 2024, then surged by 495.29% to $102.3 million in 2025, then slumped by 74.82% to $25.8 million in 2026.
• Business Quant data shows CBIO's Operating Expenses at $25.8 million in Q1 2026, $102.3 million in Q4 2025, and $25.9 million in Q3 2025.